CIPHER PHARMACEUTICALS INC (TSX:CPH.TO)

Thursday, November 10, 2022, 12:20 PM
Cipher Pharmaceuticals Inc. Severely Undervalued Based on Peer Multiples
Tuesday, September 27, 2022, 9:10 AM
Preliminary Look At Cipher Pharmaceuticals Shows It Meets 10/10 Tier One Quality Microcap Requirements
See All Articles and Reports...
Sunday, May 11, 2025, 4:29 PM
Real Signals, Not Just Hype: A Deep-Dive Open Forum Event [GeoWire Weekly No. 186] | TGEN ACFN PSIX CURI FSI FALC MOJO VMD FTK MUEL BURCA CSBR BLM.V
Sunday, May 4, 2025, 11:23 AM
If Warren Buffett Invested In Microcaps, This Would Be The One (New Pick) [GeoWire Weekly No. 185] | US: TGEN, ATGN, SPOK, PPIH, BURCA | Ca: URL.CN, CPH.TO, ZOMD.V, NTE.V
Sunday, April 13, 2025, 3:28 PM
TSSI And CSBR Showed What Early Bullish Signals Can Become. Now, PPIH, CURI & KEQU Are Flashing Signals [GeoWire Weekly No. 182]
See All GeoWire Weekly...

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. Its commercial products include Epuris (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; Ozenoxacin to treat adult and paediatric patients with impetigo; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; BRINAVESS, a treatment for sinus rhythm in adults; and AGGRASTAT, an intravenous anti-platelet drug. The company's licensed products comprise CIP-Isotretinoin; Lipofen (CIP-Fenofibrate), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and Conzip/Durela (CIP- Tramadol), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain. Its pipeline products include Trevyent, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension; CF-101 for severe plaque psoriasis and rheumatoid arthritis; MOB-015, a topical formulation of terbinafine for the treatment of onychomycosis; and DTR-001, a tattoo removal cream. Cipher Pharmaceuticals Inc. was founded in 2000 and is headquartered in Oakville, Canada.

Last updated September 26, 2022


Market Data powered by QuoteMedia. Terms of Use